More Website Templates at TemplateMonster.com and Zerotheme.com

Medica Venture Partners

About Us

Big Dreams, Daring Vision and Exciting Ideas

Innovation can create paradigm shifts in healthcare, along with significant financial returns for investors. With over 100 years of experience, Medica knows that this requires building a solid business on a platform of experience, discipline and capital. We validated this with a track record of an average 3x return over many exits.

Medica pioneered healthcare investing in Israel beginning in 1995 and has provided investment capital to support companies developing breakthrough products including first and second generation percutaneous heart valves, (PVT & Ventor; acquired by Edwards LifeSciences and Medtronic) and desktop computed radiography (Orex – acquired by Kodak). With experience in all stages of company formation and growth, Medica recognizes the ‘diamond in the rough’ which less experienced investors ignore. We help develop it and bring it to the market to deliver superior returns to our investors.

We invest in:

  • Private and Public companies

  • Companies with initial revenues
    in need of growth capital

  • Financially distressed companies with proven technology

  • Companies based in Israel, the US and Europe

  • Companies in need of the next stage of management to
    facilitate growth

Medica Venture Partners

Management Team

Ehud Geller, Founder & Managing Partner

  • Co-founded Medica in 1995; veteran of
    the US and Israeli healthcare industries
    for over 30 years
  • Previously CEO of Ikapharm, CEO of Interpharm and EVP of Teva Pharmaceuticals Group
  • Former head of the Israeli Pharmaceutical Manufacturers Association and Tel Aviv Stock Exchange board member

Eli Hazum, General Partner

  • Joined Medica in 1995; scientific background – ex Weizmann Institute Professor
  • Previously with Glaxo – head of
    metabolic disease drug development
  • Successful operating experience –
    Collgard, Ester, PainReform

Henry Kay, Partner

  • Over 35 years of healthcare industry experience in marketing and strategic planning executive positions
  • Previously Group VP at Boston
    Scientific Corp
  • Former Senior VP, Sales & marketing,
    at Allergan Europe

Pennina Safer, General Partner

  • Joined Medica in 2002; healthcare industry veteran in the US and Israel
  • Strong track record in product development and biotechnology investments
  • Former VP of R&D at CBD Technologies
    (a subsidiary of FuturaGene)
  • Director of Technology Acquisitions at Genetics Institute Inc. Wyeth Pharmaceuticals

Yoav Waizer, Partner & CFO

  • Joined Medica in 2005
  • Senior financial and business
    research analysis
  • Investment experience since 1994;
    Star, Cedar

Medica Venture Partners

Next generation medical aesthetic devices for skin rejuvenation, wrinkle reduction and skin tightening; OnePulse and 3Deep technologies, provide multilayer, targeted & controlled desired clinical effects.

read more

Unique aortic valve prosthesis designed
for easy, minimally invasive implantation, improved anchoring and superior hemodynamic performance.
Acquired by Medtronic in Feb.2009.

read more

Specialized catheter-based delivery
systems for interventional cardiovascular procedures; Deliver, Lock, and Deploy devices anywhere on any guidewire. Acquired by Allium Medical

read more

Cutting edge telemetric technology
enables implantable devices to communicate potential life threatening conditions.
Acquired by Boston Scientific Corporation in June 2007.

read more

3D navigation systems (CT-guided bronchoscopy) for minimally-invasive diagnosis and treatment of lung disease.
Acquired by Covidien in May 2012


read more

TempostatinTM - novel therapy for
cancer, restenosis & fibrosis.
Acquired by Halo Therapeutics


read more

Revolutionary products for minimally-invasive replacement of heart valves.
Acquired by Edwards Life Sciences
in February 2004.



read more

Diagnostics products for chronic diseases: World leader in blood glucose monitoring for diabetes.
Acquired by J&J.



read more

Reformulated products to enhance efficacy, reduce adverse effects and increase convenience for pain treatment.


read more

GelrinTM device for cartilage and other tissue repair.




read more

Novel, proprietary, solutions for Spinal Stabilization and Long Bone Fracture Fixation. Product solutions address both previously unsolved surgical problems
and underserved markets.

read more

Global leader in medical and aesthetic lasers and light-based technology for treatment of medical and cosmetic conditions.




read more

Minimally invasive intravascular systems for targeted renal therapy.
Acquired by AngioDynamics in January 2009.


read more

Desktop computed radiography: no films, no chemicals, PC based.
Acquired by Kodak in March 2005.

read more

Developing innovative drugs for the treatment of debilitating central nervous system (CNS) disorders. IPO: NASDAQ: MEMY, April 2004.
Acquired by Roche in December 2008.


read more

Technology for disease targeting agents and gamma detecting medical devices designed to provide surgeons with the location of hidden cancer during surgery.
Company was subsidiary of NASDAQ: NEOP.OB.

read more

Innovative drug delivery solutions for the pharmaceutical and skincare industries, using proprietary technology for microencapsulation in silica.

read more

Proprietary DynamixFitTM technology for metabolic disorder, inflammatory disease, and cancer drug discovery.


read more

TarmogenTM therapy to mobilize the immune system for the treatment of cancer and infectious disease.



read more

Integrated cardiac assist blood pump for interventional cardiology and cardiac surgery.
Acquired by ABiomed in April 2005.



read more

Breakthrough medical devices for non-invasive treatment of cardiovascular and pulmonary diseases.
IPO:TASE:INCR, July 2007.

read more

New drugs providing a paradigm shift in treatment of neurological disorders.
Acquired by Amarin Corporation in December 2007.

read more

Human therapeutic antibodies, and small molecules for Hepatitis B and C & related liver transplants.
IPO:LSE: XTL, 2000. NASDAQ: XTLB.



read more
© 2013, Medica Venture Partners, All Rights Reserved.

Medica Venture Partners

Our Location

Medica Venture Partners
4 HaSadnaot St. Kohav Herzliya Bldg.
Herzliya 46728

Contact

+972 (9) 960-1900Telephone:
+972 (9) 954-2266FAX:
info@MedicaVP.com E-mail: